NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00004208,Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome,https://clinicaltrials.gov/study/NCT00004208,,COMPLETED,The main objective of this trial is to evaluate the efficacy and toxicity of intensive immuno-suppression with ATG + CSA versus best supportive care in patients with transfusion dependent low and intermediate risk myelodysplastic syndrome (MDS).,NO,Myelodysplastic Syndromes,DRUG: ATG + CSA|BEHAVIORAL: Supportive care,"Best response rate (CR + PR), 6 months","Response rate at month 3, time to response, quality and duration of response, and proportions of relapse/progression in responders, 2 and 5 years after first response|Overall survival, 2 and 5 years|Leukemia-free survival, 2 and 5 years|Transformation-free survival, 2 and 5 years",,Swiss Group for Clinical Cancer Research,,ALL,"ADULT, OLDER_ADULT",PHASE3,86,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: FACTORIAL|Masking: NONE|Primary Purpose: TREATMENT,SAKK 33/99|SWS-SAKK-33/99,2000-08,2006-10,2011-10,2003-01-27,,2015-03-11,"Universitaetsspital-Basel, Basel, CH-4031, Switzerland",
